A Phase 3 interventional study of Bupropion and Bupropion Matching Placebo in Depressive Disorder, Major, sponsored by GlaxoSmithKline. Completed at 20 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-02-25.
Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 37 studies testing bupropion in Depressive Disorder, Major — 1 open to participants now, 3 under way, none of them phase 3. Bupropion · Depressive Disorder, Major.
Among the 37 studies testing bupropion in Depressive Disorder, Major, this one is the 3rd largest by enrollment, is the only one that started in 2015, is one of 7 in phase 3, and was the 26th registered.
3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.
Browse Depressive Disorder, Major studies →1 of the 37 studies testing bupropion in Depressive Disorder, Major is open now. Recruiting first, the newest first:
Bausch Health Americas, Inc.
Ages 7–17
Bupropion: first FDA approval 1985 (WELLBUTRIN), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 414 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
37 studies; the count open now beside each. This study's row is marked.
First in 2001; this study’s year is marked. 1 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 534 is above the median of 80 across 2,534 interventional studies indexed under Depressive Disorder, Major.
Median enrollment 74 across the 37 interventional studies. Of the 32 that completed or were terminated, 17 (53%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 37 have an industry lead sponsor. The 10 most frequent:
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
29 studies in Depressive Disorder, Major by GlaxoSmithKline: none open now, none under way, none of them phase 3. Of 29 finished, 8 (28%) have results posted.
Among the 29 studies in Depressive Disorder, Major by GlaxoSmithKline, this one is the 5th largest by enrollment of the 27 interventional ones that give a count, is the only one that started in 2015, is one of 8 in phase 3, and was the 27th registered.
GlaxoSmithKline’s Depressive Disorder, Major studies by the year they started, since 2002.
1 of the studies testing bupropion in Depressive Disorder, Major that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05273996David SteffensPredictors of Cognitive Outcomes in Geriatric Depression | 2027-04-30 |
Add it to your calendar (.ics) → With an account.
Among the 37 studies testing bupropion in Depressive Disorder, Major, from their registry updates:
Among GlaxoSmithKline’s 29 in Depressive Disorder, Major:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This multi-centre study will follow a randomised, double-blind, parallel-group, active-controlled design and will evaluate the efficacy, safety and tolerability of bupropion extended-release (XL) (300 mg/day) compared with escitalopram (10-20 mg/day) in outpatients and inpatients with major depressive disorder (MDD). The total duration of the study will be 11 weeks consisting of three phases. The screening phase (phase I) will be lasting for 0-14 days, subjects will be randomised to bupropion XL or escitalopram in a 1:1 ratio for acute phase treatment phase (phase II) for 8 weeks. There are 3 dose levels during this acute treatment phase. The 3-dose level plan is designed to ensure each drug is titrated according to the prescribing information and to reach an optimal clinical dose. Finally patients will enter the taper phase (phase III) for up to 1 week to assess and reduce the possible withdrawal symptoms.
In China almost all existing antidepressants are available on the market, but bupropion XL has not yet been approved. This Phase III clinical trial will be used for the purpose of registering bupropion XL in China.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subject will receive bupropion in 3 dose levels along with escitalopram matching placebo to maintain the blind in acute treatment phase. At dose level 1 (Week 0 to Week 1), Subjects will receive bupropion XL 150 milligram (mg) per day for a week. At dose level 2 (Week 1 to Week 4), bupropion XL dose will be increased to 300mg/day for further 3 weeks. At dose level 3 (Week 4 to Week 8), bupropion XL dose will be maintained at 300mg/day. Subjects intolerable to dose level 3 will be allowed to down titrate to dose level 2 at anytime, and maintain the dose until the end of acute treatment phase (Week 8, Visit 7). At the end of acute treatment phase, the dose of bupropion XL will be reduced to 150mg/day for 1 week before discontinuation.
Drug: Bupropion · Drug: Escitalopram Matching Placebo
Subject will receive escitalopram in 3 dose levels along with bupropion matching placebo to maintain the blind in acute treatment phase. At dose level 1 (Week 0 to Week 1), Subjects will receive escitalopram 10mg/day for a week. At dose level 2 (Week 1 to Week 4), escitalopram dose will be maintained at 10mg/day for further 3 weeks. At dose level 3 (Week 4 to Week 8), escitalopram dose will be increased to 20mg/day. Subjects intolerable to dose level 3 will be allowed to down titrate to dose level 2 at anytime, and maintain the dose until the end of acute treatment phase (Week 8, Visit 7). At the end of acute treatment phase, the dose of escitalopram 20mg/day, the dose will be reduced to 10 mg/day for 1 week before discontinuation, while those receiving 10mg/day will discontinuation directly.
Drug: Bupropion Matching Placebo · Drug: Escitalopram
Bupropion is an extended-release plain creamy white colored tablet which contains bupropion hydrochloride equivalent to 150 mg of bupropion.
Bupropion hydrochloride matching placebo tablets will be supplied to maintain blinding
Escitalopram is available as a Swedish orange capsule containing escitalopram oxalate equivalent to 10 mg of escitalopram.
Escitalopram oxalate matching placebo tablets will be supplied to maintain blinding
Mean Change in Hamilton Depression Rating Scale - 17 (HAMD-17) Total Score From Baseline to End of Acute Treatment Phase (Week 8)
HAMD-17 is used to assess the severity of depression and symptom improvement. It consisted of 17 questions. The HAMD-17 total score is calculated by summing the individual response scores if there is no missing response. HAMD-17 has a total score in a range of 0 (not present) to 52 (severe). Change from Baseline was calculated by subtracting the Baseline total score (at Day 0, Week 0) from Week 8 observed total score. The Per Protocol (PP) Population is defined as all randomized participants in the Intent-To-Treat (ITT) Population who do not meet criteria of a major protocol deviation, with overall compliance of active drug for acute treatment phase in the range of 75%-125% and complete the first 6 weeks treatment and has HAMD-17 assessment at/after week 6 (that is \>=35 days). All participants in the PP population were included in the mixed model repeated measures analysis. Only those participants with data available at the specified time point were analyzed.
Time frame: Baseline (Week 0) and Week 8
Response Rate Based on HAMD-17 Total Score
HAMD-17 is an extensively used tool to assess the severity of depression and symptom improvement during the treatment. The HAMD-17 adopted for this study consisted of 17 questions with multiple choice responses, each of which is numerically scored. The HAMD-17 total score is calculated by summing the individual response scores if there is no missing response. HAMD-17 has a total score in a range of 0 (not present) to 52 (severe). Values at Day 0, Week 0 was considered as Baseline value. Response was defined as decrease in HAMD-17 total scores at end of acute treatment phase (Week 8) relative to Baseline by at least 50%. Non-responder Imputation was used in calculation of rates.
Time frame: Up to Week 8
Remission Rate Based on HAMD-17 Total Score
HAMD-17 is an extensively used tool to assess the severity of depression and symptom improvement during the treatment. The HAMD-17 adopted for this study consisted of 17 questions with multiple choice responses, each of which is numerically scored. The HAMD-17 total score is calculated by summing the individual response scores if there is no missing response. HAMD-17 has a total score in a range of 0 (not present) to 52 (severe). Values at Day 0, Week 0 was considered as Baseline value. Remission was defined as HAMD-17 total scores at end of acute treatment phase (Week 8) \<=7.
Time frame: Up to Week 8
Sustained Response Rate Based on HAMD-17 Total Score
HAMD-17 is an extensively used tool to assess the severity of depression and symptom improvement during the treatment. The HAMD-17 adopted for this study consisted of 17 questions with multiple choice responses, each of which is numerically scored. The HAMD-17 total score is calculated by summing the individual response scores if there is no missing response. HAMD-17 has a total score in a range of 0 (not present) to 52 (severe). Values at Day 0, Week 0 was considered as Baseline value. Sustained response was defined as response at end of acute treatment phase and an earlier visit and the decrease from Baseline in non-missing HAMD-17 total scores at all visits between these two visits by at least 40%.
Time frame: Up to Week 8
Sustained Remission Rate Based on HAMD-17 Total Score
HAMD-17 is an extensively used tool to assess the severity of depression and symptom improvement during the treatment. The HAMD-17 adopted for this study consisted of 17 questions with multiple choice responses, each of which is numerically scored. The HAMD-17 total score is calculated by summing the individual response scores if there is no missing response. HAMD-17 has a total score in a range of 0 (not present) to 52 (severe). Values at Day 0, Week 0 was considered as Baseline value. Sustained remission was defined as remission at end of acute treatment phase and an earlier visit and non-missing HAMD-17 total scores at all visits between these two visits \<=8.
Time frame: Up to Week 8
Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at Weeks 1, 2, 4, 6 and 8
MADRS is a 10-point rating scale. Each item is scored on a scale of 0-6, with a total score range of 0-60. Higher score indicates worst symptoms. This scale is mainly used to assess the efficacy of antidepressant treatment. The ratings were based on the signs and symptoms during the preceding week prior to the visit. Values at Day0, Week 0 was considered as Baseline value. The observed MADRS total score was considered as missing if any item is missing. Change from Baseline in MADRS was obtained by subtracting the Baseline value from the specific post-Baseline value. All participants in the PP population were analyzed and n=X in the category titles represented the number of participants with data available at the specified time points.
Time frame: Baseline (Week 0) and Weeks 1, 2, 4, 6 and 8
Change From Baseline in HAMD-17 Depressed Mood Subscale Score (Score of Item 1) at Weeks 1, 2, 4, 6 and 8
HAMD-17 is an extensively used tool to assess the severity of depression and symptom improvement during the treatment. The HAMD-17 adopted for this study consisted of 17 questions with multiple choice responses, each of which is numerically scored. The HAMD-17 Depressed Mood Subscale is a factor score of item-1 (Depressed Mood) of HAMD-17 scale. This subscale has a score in a range of 0 (absence of depressed mood feelings) to 4 (when participants report virtually only these feeling states in his/her spontaneous verbal and non-verbal communicationtotal score). Values at Day 0, Week 0 was considered as Baseline value. Change from Baseline was calculated by subtracting the Baseline response from the specific post-Baseline response. All participants in the PP population were analyzed and n=X in the category titles represented the number of participants with data available at the specified time points.
Time frame: Baseline (Week 0) and Weeks 1, 2, 4, 6 and 8
Change From Baseline in HAMD-17 Anxiety/Somatization Subscale Score (Sum of Scores of Items 10, 11, 12, 13, 15 and 17) at Weeks 1, 2, 4, 6 and 8
HAMD-17 is an extensively used tool to assess the severity of depression and symptom improvement during the treatment. The HAMD-17 adopted for this study consisted of 17 questions with multiple choice responses, each of which is numerically scored. The HAMD-17 Anxiety/Somatization subscale score was derived as sum of scores of items 10, 11, 12, 13, 15 and 17 from HAMD-17. This subscale has a score in a range of 0 (absence of condition) to 18 (most severe condition). Values at Day 0, Week 0 was considered as Baseline value. Change from Baseline was calculated by subtracting the Baseline response from the specific post-Baseline response. All participants in the PP population were analyzed and n=X in the category titles represented the number of participants with data available at the specified time points.
Time frame: Baseline (Week 0) and Weeks 1, 2, 4, 6 and 8
Change From Baseline in HAMD-17 Retardation Subscale Score (Sum of Scores of Items 1, 7, 8 and 14) at Weeks 1, 2, 4, 6 and 8
HAMD-17 is an extensively used tool to assess the severity of depression and symptom improvement during the treatment. The HAMD-17 adopted for this study consisted of 17 questions with multiple choice responses, each of which is numerically scored. The HAMD-17 Retardation subscale score was derived as sum of scores of items 1, 7, 8 and 14 from HAMD-17. This subscale has a score in a range of 0 (absence of condition) to 14 (most severe condition). Values at Day 0, Week 0 was considered as Baseline value. Change from Baseline was calculated by subtracting the Baseline response from the specific post-Baseline response. All participants in the PP population were analyzed and n=X in the category titles represented the number of participants with data available at the specified time points.
Time frame: Baseline (Week 0) and Weeks 1, 2, 4, 6 and 8
Change From Baseline in HAMD-17 Sleep Disorder Subscale Score (Sum of Scores of Items 4, 5 and 6) at Weeks 1, 2, 4, 6 and 8
HAMD-17 is an extensively used tool to assess the severity of depression and symptom improvement during the treatment. The HAMD-17 adopted for this study consisted of 17 questions with multiple choice responses, each of which is numerically scored. The HAMD-17 Sleep Disorder subscale score was derived as sum of scores of items 4, 5 and 6 from HAMD-17. This subscale has a score in a range of 0 (absence of condition) to 6 (most severe condition). Values at Day 0, Week 0 was considered as Baseline value. Change from Baseline was calculated by subtracting the Baseline response from the specific post-Baseline response. All participants in the PP population were analyzed and n=X in the category titles represented the number of participants with data available at the specified time points.
Time frame: Baseline (Week 0) and Weeks 1, 2, 4, 6 and 8
Change From Baseline in Clinical Global Impression-Severity of Illness Scale (CGI-S) Score at Weeks 1, 2, 4, 6 and 8
CGI-S records the severity of illness at specific time points, with a range of responses from 1 (normal, not at all ill) to 7 (among the most extremely ill participants). Participants with zero values (0) representing "Not assessed" were excluded from analysis. Values at Day 0, Week 0 was considered as Baseline value. Change from Baseline was obtained by subtracting the Baseline value from the specific post-Baseline value. All participants in the PP population were analyzed and n=X in the category titles represented the number of participants with data available at the specified time points.
Time frame: Baseline (Week 0) and Weeks 1, 2, 4, 6 and 8
Percentage of Participants With a Clinical Global Impression Global Improvement (CGI-I) Score of 1 ("Very Much Improved") or 2 ("Much Improved") at Weeks 1, 2, 4, 6 and 8
For CGI-I rating, the raters indicated their assessment of the participant's total improvement or worsening compared to the participant's condition at the Baseline visit, whether or not the improvement or worsening was thought to be treatment related. Scores ranges from 0 to 7 where 0 represents "Not assessed", and the remaining values 1-7 represent "Very much improved" (1) to "Very much worse" (7). Participants with score 0 were excluded from analysis. All participants in the PP population were analyzed and n=X in the category titles represented the number of participants with data available at the specified time points.
Time frame: Baseline (Week 0) and Weeks 1, 2, 4, 6 and 8
Number of Participants With Any Non-serious Adverse Event (AE) and Any Serious AE (SAE)
An AE is any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Any untoward event resulting in death, life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, congenital anomaly/birth defect, any other situation according to medical or scientific judgment that may not be immediately life-threatening or result in death or hospitalization but may jeopardize the participant or may require medical or surgical intervention or all events of possible drug-induced liver injury with hyperbilirubinemia were categorized as SAE. Participants who received any of the study treatment and had any non-serious AE or SAE were considered for analysis. Safety Population comprised of all participants who took at least one dose of the study medication.
Time frame: Up to Week 10
Change From Baseline in Hemoglobin, Total Protein, Albumin and Mean Corpuscle Hemoglobin Concentration (MCHC) at the Indicated Time Points
Blood samples were collected at Screening (within 14 days prior to dosing) and at Week 8, Taper visit (Week 9) and Follow-up visit (Week 10). Baseline was considered as the value obtained at Screening. Change from Baseline was calculated by subtracting the Baseline value from the specific post-Baseline values. Only those participants with data available at the specified time points were analyzed (represented by n=X in the category titles).
Time frame: Up to Week 10
Change From Baseline in Hematocrit at the Indicated Time Points
Blood samples were collected at Screening (within 14 days prior to dosing) and at Week 8, Taper visit (Week 9) and Follow-up visit (Week 10). Baseline was considered as the value obtained at Screening. Change from Baseline was calculated by subtracting the Baseline value from the specific post-Baseline values. Only those participants with data available at the specified time points were analyzed (represented by n=X in the category titles).
Time frame: Up to Week 10
Change From Baseline in White Blood Cell (WBC) Count, Total Neutrophil, Lymphocyte, Basophil, Eosinophil, Monocyte and Platelet Count at the Indicated Time Points
Blood samples were collected at Screening (within 14 days prior to dosing) and at Week 8, Taper visit (Week 9) and Follow-up visit (Week 10). Baseline was considered as the value obtained at Screening. Change from Baseline was calculated by subtracting the Baseline value from the specific post-Baseline values. Only those participants with data available at the specified time points were analyzed (represented by n=X in the category titles).
Time frame: Up to Week 10
Change From Baseline in Total Bilirubin, Direct Bilirubin and Creatinine at the Indicated Time Points
Blood samples were collected at Screening (within 14 days prior to dosing) and at Week 8, Taper visit (Week 9) and Follow-up visit (Week 10). Baseline was considered as the value obtained at Screening. Change from Baseline was calculated by subtracting the Baseline value from the specific post-Baseline values. Only those participants with data available at the specified time points were analyzed (represented by n=X in the category titles).
Time frame: Up to Week 10
Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), Gamma-glutamyl Transpeptidase (GGT) and Lactose Dehydrogenase (LD) at the Indicated Time Points
Blood samples were collected at Screening (within 14 days prior to dosing) and at Week 8, Taper visit (Week 9) and Follow-up visit (Week 10). Baseline was considered as the value obtained at Screening. Change from Baseline was calculated by subtracting the Baseline value from the specific post-Baseline values. Only those participants with data available at the specified time points were analyzed (represented by n=X in the category titles).
Time frame: Up to Week 10
Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, Potassium, Sodium, Triglyceride and Urea at the Indicated Time Points
Blood samples were collected at Screening (within 14 days prior to dosing) and at Week 8, Taper visit (Week 9) and Follow-up visit (Week 10). Baseline was considered as the value obtained at Screening. Change from Baseline was calculated by subtracting the Baseline value from the specific post-Baseline values. Only those participants with data available at the specified time points were analyzed (represented by n=X in the category titles).
Time frame: Up to Week 10
Change From Baseline in Mean Corpuscle Hemoglobin (MCH) at the Indicated Time Points
Blood samples were collected at Screening (within 14 days prior to dosing) and at Week 8, Taper visit (Week 9) and Follow-up visit (Week 10). Baseline was considered as the value obtained at Screening. Change from Baseline was calculated by subtracting the Baseline value from the specific post-Baseline values. Only those participants with data available at the specified time points were analyzed (represented by n=X in the category titles).
Time frame: Up to Week 10
Change From Baseline in Mean Corpuscle Volume (MCV) at the Indicated Time Points
Blood samples were collected at Screening (within 14 days prior to dosing) and at Week 8, Taper visit (Week 9) and Follow-up visit (Week 10). Baseline was considered as the value obtained at Screening. Change from Baseline was calculated by subtracting the Baseline value from the specific post-Baseline values. Only those participants with data available at the specified time points were analyzed (represented by n=X in the category titles).
Time frame: Up to Week 10
Change From Baseline in Red Blood Cell (RBC) Count at the Indicated Time Points
Blood samples were collected at Screening (within 14 days prior to dosing) and at Week 8, Taper visit (Week 9) and Follow-up visit (Week 10). Baseline was considered as the value obtained at Screening. Change from Baseline was calculated by subtracting the Baseline value from the specific post-Baseline values. Only those participants with data available at the specified time points were analyzed (represented by n=X in the category titles).
Time frame: Up to Week 10
Number of Participants With Urinalysis Data Outside the Normal Range
Urine samples were collected at Screening (within 14 days prior to dosing) and at Week 8, Taper visit (Week 9) and Follow-up visit (Week 10). Number of participants with urine specific gravity and potential of hydrogen (pH) outside (higher or lower) the normal range are presented. Only those participants with data available at the specified time points were analyzed (represented by n=X in the category titles).
Time frame: Up to Week 10
Number of Participants With Vital Sign Parameters Outside the Clinical Concern Range
Vital signs including systolic blood pressure (SBP), diastolic blood pressure (DBP) and heart rate (HR) were taken at Screening (within 14 days prior to dosing), randomization visit (Week 0) and at Weeks 1, 2, 4, 6, 8, Taper visit (Week 9) and Follow-up visit (Week 10). SBP \<30 or \>170 millimeter of mercury (mmHg); DBP \<20 or \>110 mmHg and heart rate \<40 or \>120 beats per minute (bpm) were considered as values outside of clinical concern range and were presented as 'High' or 'Low' values. Number of participants with vital signs outside of clinical concern range at any post-Baseline visit are presented. Only those participants with data available at the specified time points were analyzed.
Time frame: Up to Week 10
Number of Participants With Electrocardiogram (ECG) Data Outside the Clinical Concern Range
ECG was recorded at Screening (within 14 days prior to dosing) and at Week 8, Taper visit (Week 9) and Follow-up visit (Week 10). PR interval \<110 or \>220 millisecond (msec); QRS interval \<60 or \>120 msec and corrected QT (QTc) interval \>450 msec were considered as values outside of clinical concern range and were presented as 'High' or 'Low' values. Number of participants with ECG data outside of clinical concern range at any post-Baseline visit are presented. Only those participants with data available at the specified time points were analyzed.
Time frame: Up to Week 10
Change From Baseline in Changes in Sexual Function Questionnaire (CSFQ)
CSFQ is a questionnaire about sexual activity and sexual function (sexual intercourse, masturbation, sexual fantasies and other activity). CSFQ is a gender-specific questionnaire. Both male and female versions consist of 14 items, each with 5 possible answers. CSFQ has a score in a range of 14 to 70. Higher score indicates higher sexual activity and sexual function. Value at Day 0 (Week 0) was considered as Baseline value. Change from Baseline at Week 8 was calculated by subtracting the Baseline score from the specific post-Baseline score. Only those participants with data available at the specified time points were analyzed.
Time frame: Baseline (Day 0) and Week 8
Number of Participants With Suicidal Ideation or Behavior During Treatment Assessed by Columbia Suicide Severity Rating Scale (C-SSRS)
C-SSRS is an assessment tool that evaluates suicidal ideation and behavior. It consists of 10 items, each with two possible answers (yes/no). Suicidal ideation was interpreted if "yes" answer at any time during treatment to any one of the five suicidal ideation questions (item 1-5) on the C-SSRS. Suicidal behavior was interpreted if a "yes" answer at any time during treatment to any one of the five suicidal behavior questions (item 6-10) on the C-SSRS. Suicidal ideation or behavior is interpreted if a "yes" answer at any time during treatment to any one of the ten suicidal ideation and behavior questions (item 1-10) on the C-SSRS. Number of participants with at least one on-treatment C-SSRS assessment were analyzed. Only those participants with data available at the specified time points were analyzed.
Time frame: Baseline and up to Taper visit (Week 9)
This was a multi-center, randomized, double-blind, parallel active-controlled study to evaluate the efficacy, safety and tolerability of bupropion hydrochloride extended-release (XL) and escitalopram oxalate in participants with major depressive disorder. This study was conducted in China from 10-February-2015 to 25-October-2016.
| Milestone | Bupropion XL | Escitalopram |
|---|---|---|
| Started | 266 | 268 |
| Completed | 183 | 198 |
| Not completed | 83 | 70 |
| Withdrew: Adverse event | 28 | 17 |
| Withdrew: Lack of efficacy | 10 | 5 |
| Withdrew: Protocol violation | 0 | 3 |
| Withdrew: Met protocol-defined stopping criteria | 5 | 4 |
| Withdrew: Lost to follow-up | 10 | 11 |
| Withdrew: Physician decision | 8 | 3 |
| Withdrew: Withdrawal by subject | 22 | 27 |
HAMD-17 is used to assess the severity of depression and symptom improvement. It consisted of 17 questions. The HAMD-17 total score is calculated by summing the individual response scores if there is no missing response. HAMD-17 has a total score in a range of 0 (not present) to 52 (severe). Change from Baseline was calculated by subtracting the Baseline total score (at Day 0, Week 0) from Week 8 observed total score. The Per Protocol (PP) Population is defined as all randomized participants in the Intent-To-Treat (ITT) Population who do not meet criteria of a major protocol deviation, with overall compliance of active drug for acute treatment phase in the range of 75%-125% and complete the first 6 weeks treatment and has HAMD-17 assessment at/after week 6 (that is \>=35 days). All participants in the PP population were included in the mixed model repeated measures analysis. Only those participants with data available at the specified time point were analyzed.
| Scores on a scale | Bupropion XL | Escitalopram |
|---|---|---|
| Mean Change in Hamilton Depression Rating Scale - 17 (HAMD-17) Total Score From Baseline to End of Acute Treatment Phase (Week 8) | -14.5 ± 0.41 | -15.4 ± 0.39 |
HAMD-17 is an extensively used tool to assess the severity of depression and symptom improvement during the treatment. The HAMD-17 adopted for this study consisted of 17 questions with multiple choice responses, each of which is numerically scored. The HAMD-17 total score is calculated by summing the individual response scores if there is no missing response. HAMD-17 has a total score in a range of 0 (not present) to 52 (severe). Values at Day 0, Week 0 was considered as Baseline value. Response was defined as decrease in HAMD-17 total scores at end of acute treatment phase (Week 8) relative to Baseline by at least 50%. Non-responder Imputation was used in calculation of rates.
| Percentage of Participants | Bupropion XL | Escitalopram |
|---|---|---|
| Response Rate Based on HAMD-17 Total Score | 69.6 | 72.9 |
HAMD-17 is an extensively used tool to assess the severity of depression and symptom improvement during the treatment. The HAMD-17 adopted for this study consisted of 17 questions with multiple choice responses, each of which is numerically scored. The HAMD-17 total score is calculated by summing the individual response scores if there is no missing response. HAMD-17 has a total score in a range of 0 (not present) to 52 (severe). Values at Day 0, Week 0 was considered as Baseline value. Remission was defined as HAMD-17 total scores at end of acute treatment phase (Week 8) \<=7.
| Percentage of Participants | Bupropion XL | Escitalopram |
|---|---|---|
| Remission Rate Based on HAMD-17 Total Score | 39.7 | 47.2 |
HAMD-17 is an extensively used tool to assess the severity of depression and symptom improvement during the treatment. The HAMD-17 adopted for this study consisted of 17 questions with multiple choice responses, each of which is numerically scored. The HAMD-17 total score is calculated by summing the individual response scores if there is no missing response. HAMD-17 has a total score in a range of 0 (not present) to 52 (severe). Values at Day 0, Week 0 was considered as Baseline value. Sustained response was defined as response at end of acute treatment phase and an earlier visit and the decrease from Baseline in non-missing HAMD-17 total scores at all visits between these two visits by at least 40%.
| Percentage of Participants | Bupropion XL | Escitalopram |
|---|---|---|
| Sustained Response Rate Based on HAMD-17 Total Score | 51.6 | 56.3 |
HAMD-17 is an extensively used tool to assess the severity of depression and symptom improvement during the treatment. The HAMD-17 adopted for this study consisted of 17 questions with multiple choice responses, each of which is numerically scored. The HAMD-17 total score is calculated by summing the individual response scores if there is no missing response. HAMD-17 has a total score in a range of 0 (not present) to 52 (severe). Values at Day 0, Week 0 was considered as Baseline value. Sustained remission was defined as remission at end of acute treatment phase and an earlier visit and non-missing HAMD-17 total scores at all visits between these two visits \<=8.
| Percentage of Participants | Bupropion XL | Escitalopram |
|---|---|---|
| Sustained Remission Rate Based on HAMD-17 Total Score | 25.5 | 28.6 |
MADRS is a 10-point rating scale. Each item is scored on a scale of 0-6, with a total score range of 0-60. Higher score indicates worst symptoms. This scale is mainly used to assess the efficacy of antidepressant treatment. The ratings were based on the signs and symptoms during the preceding week prior to the visit. Values at Day0, Week 0 was considered as Baseline value. The observed MADRS total score was considered as missing if any item is missing. Change from Baseline in MADRS was obtained by subtracting the Baseline value from the specific post-Baseline value. All participants in the PP population were analyzed and n=X in the category titles represented the number of participants with data available at the specified time points.
| Scores on a scale | Bupropion XL | Escitalopram |
|---|---|---|
| Week 1, n=184, 199 | -3.6 ± 0.34 | -3.8 ± 0.33 |
| Week 2, n=182, 199 | -7.0 ± 0.47 | -8.3 ± 0.45 |
| Week 4, n=184, 198 | -11.2 ± 0.58 | -12.4 ± 0.56 |
| Week 6, n=183, 196 | -15.5 ± 0.59 | -16.3 ± 0.57 |
| Week 8, n=176, 188 | -18.6 ± 0.57 | -19.5 ± 0.55 |
HAMD-17 is an extensively used tool to assess the severity of depression and symptom improvement during the treatment. The HAMD-17 adopted for this study consisted of 17 questions with multiple choice responses, each of which is numerically scored. The HAMD-17 Depressed Mood Subscale is a factor score of item-1 (Depressed Mood) of HAMD-17 scale. This subscale has a score in a range of 0 (absence of depressed mood feelings) to 4 (when participants report virtually only these feeling states in his/her spontaneous verbal and non-verbal communicationtotal score). Values at Day 0, Week 0 was considered as Baseline value. Change from Baseline was calculated by subtracting the Baseline response from the specific post-Baseline response. All participants in the PP population were analyzed and n=X in the category titles represented the number of participants with data available at the specified time points.
| Scores on a scale | Bupropion XL | Escitalopram |
|---|---|---|
| Week 1, n=184, 199 | -0.4 ± 0.04 | -0.4 ± 0.04 |
| Week 2, n=182, 199 | -0.7 ± 0.06 | -0.8 ± 0.05 |
| Week 4, n=184, 198 | -1.1 ± 0.06 | -1.3 ± 0.06 |
| Week 6, n=183, 197 | -1.5 ± 0.06 | -1.6 ± 0.06 |
| Week 8, n=176, 188 | -1.9 ± 0.06 | -1.9 ± 0.06 |
HAMD-17 is an extensively used tool to assess the severity of depression and symptom improvement during the treatment. The HAMD-17 adopted for this study consisted of 17 questions with multiple choice responses, each of which is numerically scored. The HAMD-17 Anxiety/Somatization subscale score was derived as sum of scores of items 10, 11, 12, 13, 15 and 17 from HAMD-17. This subscale has a score in a range of 0 (absence of condition) to 18 (most severe condition). Values at Day 0, Week 0 was considered as Baseline value. Change from Baseline was calculated by subtracting the Baseline response from the specific post-Baseline response. All participants in the PP population were analyzed and n=X in the category titles represented the number of participants with data available at the specified time points.
| Scores on a scale | Bupropion XL | Escitalopram |
|---|---|---|
| Week 1, n=184, 199 | -1.3 ± 0.12 | -1.1 ± 0.12 |
| Week 2, n=182, 199 | -2.0 ± 0.15 | -2.4 ± 0.14 |
| Week 4, n=184, 198 | -3.0 ± 0.19 | -3.4 ± 0.18 |
| Week 6, n=183, 197 | -4.0 ± 0.17 | -4.4 ± 0.17 |
| Week 8, n=176, 188 | -4.8 ± 0.16 | -5.1 ± 0.16 |
HAMD-17 is an extensively used tool to assess the severity of depression and symptom improvement during the treatment. The HAMD-17 adopted for this study consisted of 17 questions with multiple choice responses, each of which is numerically scored. The HAMD-17 Retardation subscale score was derived as sum of scores of items 1, 7, 8 and 14 from HAMD-17. This subscale has a score in a range of 0 (absence of condition) to 14 (most severe condition). Values at Day 0, Week 0 was considered as Baseline value. Change from Baseline was calculated by subtracting the Baseline response from the specific post-Baseline response. All participants in the PP population were analyzed and n=X in the category titles represented the number of participants with data available at the specified time points.
| Scores on a scale | Bupropion XL | Escitalopram |
|---|---|---|
| Week 1, n=184, 199 | -1.0 ± 0.10 | -1.0 ± 0.10 |
| Week 2, n=182, 199 | -1.8 ± 0.13 | -2.0 ± 0.13 |
| Week 4, n=184, 198 | -2.9 ± 0.15 | -3.1 ± 0.15 |
| Week 6, n=183, 197 | -3.9 ± 0.16 | -3.9 ± 0.16 |
| Week 8, n=176, 188 | -4.7 ± 0.17 | -4.9 ± 0.16 |
HAMD-17 is an extensively used tool to assess the severity of depression and symptom improvement during the treatment. The HAMD-17 adopted for this study consisted of 17 questions with multiple choice responses, each of which is numerically scored. The HAMD-17 Sleep Disorder subscale score was derived as sum of scores of items 4, 5 and 6 from HAMD-17. This subscale has a score in a range of 0 (absence of condition) to 6 (most severe condition). Values at Day 0, Week 0 was considered as Baseline value. Change from Baseline was calculated by subtracting the Baseline response from the specific post-Baseline response. All participants in the PP population were analyzed and n=X in the category titles represented the number of participants with data available at the specified time points.
| Scores on a scale | Bupropion XL | Escitalopram |
|---|---|---|
| Week 1, n=184, 199 | -0.6 ± 0.10 | -0.7 ± 0.09 |
| Week 2, n=182, 199 | -0.8 ± 0.11 | -1.2 ± 0.10 |
| Week 4, n=184, 198 | -1.4 ± 0.11 | -1.6 ± 0.11 |
| Week 6, n=183, 197 | -1.8 ± 0.11 | -2.0 ± 0.11 |
| Week 8, n=176, 188 | -2.3 ± 0.11 | -2.4 ± 0.11 |
CGI-S records the severity of illness at specific time points, with a range of responses from 1 (normal, not at all ill) to 7 (among the most extremely ill participants). Participants with zero values (0) representing "Not assessed" were excluded from analysis. Values at Day 0, Week 0 was considered as Baseline value. Change from Baseline was obtained by subtracting the Baseline value from the specific post-Baseline value. All participants in the PP population were analyzed and n=X in the category titles represented the number of participants with data available at the specified time points.
| Scores on a scale | Bupropion XL | Escitalopram |
|---|---|---|
| Week 1, n=184, 199 | -0.3 ± 0.04 | -0.4 ± 0.04 |
| Week 2, n=182, 199 | -0.7 ± 0.05 | -0.8 ± 0.05 |
| Week 4, n=184, 198 | -1.1 ± 0.07 | -1.3 ± 0.06 |
| Week 6, n=183, 197 | -1.6 ± 0.07 | -1.7 ± 0.07 |
| Week 8, n=176, 188 | -2.1 ± 0.07 | -2.2 ± 0.07 |
For CGI-I rating, the raters indicated their assessment of the participant's total improvement or worsening compared to the participant's condition at the Baseline visit, whether or not the improvement or worsening was thought to be treatment related. Scores ranges from 0 to 7 where 0 represents "Not assessed", and the remaining values 1-7 represent "Very much improved" (1) to "Very much worse" (7). Participants with score 0 were excluded from analysis. All participants in the PP population were analyzed and n=X in the category titles represented the number of participants with data available at the specified time points.
| Percentage of Participants | Bupropion XL | Escitalopram |
|---|---|---|
| Week 1, n=184, 199 | 6 | 7.5 |
| Week 2, n=182, 199 | 21.4 | 22.1 |
| Week 4, n=184, 198 | 38.6 | 52.5 |
| Week 6, n=183, 197 | 67.8 | 71.6 |
| Week 8, n=176, 188 | 80.7 | 83.5 |
An AE is any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Any untoward event resulting in death, life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, congenital anomaly/birth defect, any other situation according to medical or scientific judgment that may not be immediately life-threatening or result in death or hospitalization but may jeopardize the participant or may require medical or surgical intervention or all events of possible drug-induced liver injury with hyperbilirubinemia were categorized as SAE. Participants who received any of the study treatment and had any non-serious AE or SAE were considered for analysis. Safety Population comprised of all participants who took at least one dose of the study medication.
| Participants | Bupropion XL | Escitalopram |
|---|---|---|
| Any non-serious AE | 151 | 150 |
| Any SAE | 10 | 11 |
Blood samples were collected at Screening (within 14 days prior to dosing) and at Week 8, Taper visit (Week 9) and Follow-up visit (Week 10). Baseline was considered as the value obtained at Screening. Change from Baseline was calculated by subtracting the Baseline value from the specific post-Baseline values. Only those participants with data available at the specified time points were analyzed (represented by n=X in the category titles).
| Gram per Liter (G/L) | Bupropion XL | Escitalopram |
|---|---|---|
| Hemoglobin, Week 8, n=176, 183 | -0.22 ± 7.621 | -1.16 ± 7.874 |
| Hemoglobin, Taper, n=13, 16 | -1.54 ± 5.868 | 1.38 ± 8.057 |
| Hemoglobin, Follow-up, n=10, 8 | -3.10 ± 12.449 | 0.38 ± 6.163 |
| Total protein, Week 8, n=174, 183 | -0.640 ± 5.2784 | -0.891 ± 4.0339 |
| Total protein, Taper, n=12, 15 | 1.197 ± 6.9347 | 2.000 ± 8.7513 |
| Total protein, Follow-up, n=8, 12 | -4.650 ± 5.5131 | -1.227 ± 4.8619 |
| Albumin, Week 8, n=175, 183 | -0.254 ± 3.0207 | -0.678 ± 2.8483 |
| Albumin, Taper, n=12, 15 | -0.086 ± 3.9688 | -0.027 ± 4.2372 |
| Albumin, Follow-up, n=8, 12 | -1.925 ± 2.0084 | -1.577 ± 3.6313 |
| MCHC, Week 8, n=176, 183 | -0.09 ± 8.933 | 0.76 ± 9.821 |
| MCHC, Taper, n=13, 16 | 0.54 ± 8.828 | 2.25 ± 9.030 |
| MCHC, Follow-up, n=10, 8 | -2.10 ± 9.398 | -2.88 ± 5.055 |
Blood samples were collected at Screening (within 14 days prior to dosing) and at Week 8, Taper visit (Week 9) and Follow-up visit (Week 10). Baseline was considered as the value obtained at Screening. Change from Baseline was calculated by subtracting the Baseline value from the specific post-Baseline values. Only those participants with data available at the specified time points were analyzed (represented by n=X in the category titles).
| Proportion of red blood cells in blood | Bupropion XL | Escitalopram |
|---|---|---|
| Hematocrit, Week 8, n=176, 183 | 0.0016 ± 0.06088 | -0.0044 ± 0.02587 |
| Hematocrit, Taper, n=13, 16 | -0.0051 ± 0.02105 | 0.0017 ± 0.02601 |
| Hematocrit, Follow-up, n=10, 8 | -0.0076 ± 0.04403 | 0.0051 ± 0.01509 |
Blood samples were collected at Screening (within 14 days prior to dosing) and at Week 8, Taper visit (Week 9) and Follow-up visit (Week 10). Baseline was considered as the value obtained at Screening. Change from Baseline was calculated by subtracting the Baseline value from the specific post-Baseline values. Only those participants with data available at the specified time points were analyzed (represented by n=X in the category titles).
| Giga cells per liter (GI/L) | Bupropion XL | Escitalopram |
|---|---|---|
| WBC count, Week 8, n=176, 183 | -0.032 ± 1.6278 | -0.073 ± 1.6282 |
| WBC count, Taper, n=13, 16 | 0.065 ± 1.5513 | -0.715 ± 1.8547 |
| WBC count, Follow-up, n=10, 8 | -0.743 ± 1.4455 | 0.427 ± 0.9032 |
| Total Neutrophils, Week 8, n=176, 183 | 0.101 ± 1.4835 | -0.165 ± 1.5540 |
| Total Neutrophils, Taper, n=13, 16 | 0.306 ± 1.6222 | -0.772 ± 1.5656 |
| Total Neutrophils, Follow-up, n=10, 8 | -0.869 ± 1.4578 | 0.424 ± 0.7470 |
| Lymphocytes, Week 8, n=176, 183 | -0.154 ± 0.4833 | 0.072 ± 0.4190 |
| Lymphocytes, Taper, n=13, 16 | -0.242 ± 0.4843 | 0.077 ± 0.5053 |
| Lymphocytes, Follow-up, n=10, 8 | 0.042 ± 0.3937 | 0.022 ± 0.4388 |
| Basophil, Week 8, n=176, 182 | 0.001 ± 0.0173 | 0.002 ± 0.0218 |
| Basophil, Taper, n=13, 16 | 0.001 ± 0.0091 | 0.001 ± 0.0131 |
| Basophil, Follow-up, n=10, 8 | -0.003 ± 0.0163 | -0.012 ± 0.0087 |
| Eosinophil, Week 8, n=176, 182 | -0.004 ± 0.0788 | 0.010 ± 0.0899 |
| Eosinophil, Taper, n=13, 16 | -0.012 ± 0.0592 | 0.006 ± 0.0488 |
| Eosinophil, Follow-up, n=10, 8 | -0.005 ± 0.0627 | 0.019 ± 0.0813 |
| Monocyte, Week 8, n=176, 182 | 0.021 ± 0.1180 | 0.003 ± 0.1113 |
| Monocyte, Taper, n=13, 16 | -0.001 ± 0.1023 | -0.031 ± 0.0917 |
| Monocyte, Follow-up, n=10, 8 | 0.058 ± 0.1292 | 0.010 ± 0.0920 |
| Platelet count, Week 8, n=176, 183 | 7.73 ± 32.725 | 0.56 ± 29.492 |
| Platelet count, Taper, n=13, 16 | 17.15 ± 35.126 | 7.19 ± 22.448 |
| Platelet count, Follow-up, n=10, 8 | 28.50 ± 35.600 | 5.38 ± 24.784 |
Blood samples were collected at Screening (within 14 days prior to dosing) and at Week 8, Taper visit (Week 9) and Follow-up visit (Week 10). Baseline was considered as the value obtained at Screening. Change from Baseline was calculated by subtracting the Baseline value from the specific post-Baseline values. Only those participants with data available at the specified time points were analyzed (represented by n=X in the category titles).
| Micromoles per liter (µmol/L) | Bupropion XL | Escitalopram |
|---|---|---|
| Total bilirubin, Week 8, n=175, 181 | -0.812 ± 4.7591 | -0.071 ± 4.8022 |
| Total bilirubin, Taper, n=12, 15 | -3.457 ± 6.5521 | 1.198 ± 3.9442 |
| Total bilirubin, Follow-up, n=8, 12 | 0.382 ± 4.0151 | 0.338 ± 3.4710 |
| Direct bilirubin, Week 8, n=175, 180 | -0.072 ± 1.3659 | -0.006 ± 1.2310 |
| Direct bilirubin, Taper, n=11, 15 | -1.554 ± 3.7607 | 0.654 ± 1.7145 |
| Direct bilirubin, Follow-up, n=8, 12 | -0.102 ± 1.1192 | 0.382 ± 0.9070 |
| Creatinine, Week 8, n=174, 183 | 7.507 ± 10.6852 | 0.307 ± 9.0811 |
| Creatinine, Taper, n=12, 15 | 6.675 ± 6.9134 | 0.880 ± 10.3281 |
| Creatinine, Follow-up, n=8, 11 | 4.237 ± 8.9291 | 1.618 ± 9.6668 |
Blood samples were collected at Screening (within 14 days prior to dosing) and at Week 8, Taper visit (Week 9) and Follow-up visit (Week 10). Baseline was considered as the value obtained at Screening. Change from Baseline was calculated by subtracting the Baseline value from the specific post-Baseline values. Only those participants with data available at the specified time points were analyzed (represented by n=X in the category titles).
| International Units per liter (IU/L) | Bupropion XL | Escitalopram |
|---|---|---|
| ALT, Week 8, n=176, 183 | 2.254 ± 14.7208 | 1.315 ± 10.3019 |
| ALT, Taper, n=12, 16 | 7.993 ± 17.5985 | -1.812 ± 15.1544 |
| ALT, Follow-up, n=8, 12 | -7.337 ± 21.7809 | 5.938 ± 19.8234 |
| ALP, Week 8, n=176, 181 | 1.866 ± 13.2776 | 0.407 ± 11.7870 |
| ALP, Taper, n=12, 15 | 3.674 ± 11.5803 | 3.480 ± 19.2823 |
| ALP, Follow-up, n=7, 12 | 5.643 ± 9.2858 | -3.953 ± 11.6377 |
| AST, Week 8, n=176, 183 | 0.330 ± 7.6259 | 1.099 ± 6.1029 |
| AST, Taper, n=12, 16 | 3.193 ± 7.4990 | 0.381 ± 6.0938 |
| AST, Follow-up, n=8, 12 | 0.925 ± 23.3485 | 2.867 ± 11.0264 |
| GGT, Week 8, n=175, 181 | 0.688 ± 17.0699 | -0.694 ± 11.1878 |
| GGT, Taper, n=12, 15 | 1.403 ± 6.2977 | -3.133 ± 4.8019 |
| GGT, Follow-up, n=7, 12 | -2.029 ± 5.9637 | 3.916 ± 25.9888 |
| LD, Week 8, n=176, 182 | 1.292 ± 32.4627 | 2.879 ± 27.3838 |
| LD, Taper, n=13, 13 | 14.463 ± 28.9571 | -8.092 ± 55.0095 |
| LD, Follow-up, n=8, 10 | 11.037 ± 45.3316 | -4.150 ± 33.8871 |
Blood samples were collected at Screening (within 14 days prior to dosing) and at Week 8, Taper visit (Week 9) and Follow-up visit (Week 10). Baseline was considered as the value obtained at Screening. Change from Baseline was calculated by subtracting the Baseline value from the specific post-Baseline values. Only those participants with data available at the specified time points were analyzed (represented by n=X in the category titles).
| Millimole per liter (mmol/L) | Bupropion XL | Escitalopram |
|---|---|---|
| Calcium, Week 8, n=173, 183 | -0.017 ± 0.1139 | -0.020 ± 0.1225 |
| Calcium, Taper, n=12, 12 | -0.019 ± 0.1906 | 0.012 ± 0.1091 |
| Calcium, Follow-up, n=8, 11 | -0.060 ± 0.1032 | -0.060 ± 0.1352 |
| Chloride, Week 8, n=173, 182 | 0.259 ± 2.7943 | -0.293 ± 2.5913 |
| Chloride, Taper, n=10, 13 | -0.498 ± 3.2001 | -0.566 ± 2.4684 |
| Chloride, Follow-up, n=8, 8 | -0.287 ± 3.6588 | -0.178 ± 4.6453 |
| Cholesterol, Week 8, n=175, 181 | -0.122 ± 0.5855 | 0.051 ± 0.5931 |
| Cholesterol, Taper, n=12, 14 | 0.022 ± 0.5891 | 0.082 ± 0.5991 |
| Cholesterol, Follow-up, n=9, 11 | -0.124 ± 0.5149 | -0.122 ± 0.5899 |
| Glucose, Week 8, n=173, 181 | -0.051 ± 0.6327 | -0.050 ± 0.5871 |
| Glucose, Taper, n=12, 16 | 0.352 ± 0.3822 | 0.106 ± 0.9661 |
| Glucose, Follow-up, n=9, 11 | -0.194 ± 0.4089 | 0.025 ± 1.2117 |
| Potassium, Week 8, n=173, 182 | -0.021 ± 0.3504 | 0.009 ± 0.3552 |
| Potassium, Taper, n=10, 13 | -0.114 ± 0.4165 | 0.046 ± 0.5095 |
| Potassium, Follow-up, n=8, 8 | -0.110 ± 0.6221 | 0.036 ± 0.6556 |
| Sodium, Week 8, n=173, 182 | -0.205 ± 2.4757 | -0.178 ± 2.5481 |
| Sodium, Taper, n=10, 13 | -0.611 ± 3.0799 | 0.978 ± 1.5853 |
| Sodium, Follow-up, n=8, 8 | -0.175 ± 3.9085 | 0.770 ± 3.6011 |
| Triglycerides, Week 8, n=175, 181 | 0.003 ± 1.0499 | 0.022 ± 0.5844 |
| Triglycerides, Taper, n=13, 15 | -0.032 ± 0.4359 | 0.574 ± 2.0355 |
| Triglycerides, Follow-up, n=9, 11 | 0.637 ± 1.4045 | 0.181 ± 0.7767 |
| Urea, Week 8, n=174, 183 | -0.068 ± 1.3282 | 0.015 ± 1.1723 |
| Urea, Taper, n=12, 16 | 0.517 ± 0.9249 | -0.269 ± 1.0223 |
| Urea, Follow-up, n=8, 11 | 0.687 ± 0.6998 | -0.419 ± 1.0801 |
Blood samples were collected at Screening (within 14 days prior to dosing) and at Week 8, Taper visit (Week 9) and Follow-up visit (Week 10). Baseline was considered as the value obtained at Screening. Change from Baseline was calculated by subtracting the Baseline value from the specific post-Baseline values. Only those participants with data available at the specified time points were analyzed (represented by n=X in the category titles).
| Picograms | Bupropion XL | Escitalopram |
|---|---|---|
| MCH, Week 8, n=176, 183 | -0.032 ± 0.7431 | 0.049 ± 0.7052 |
| MCH, Taper, n=13, 16 | 0.269 ± 0.7941 | 0.262 ± 0.7571 |
| MCH, Follow-up, n=10, 8 | -0.050 ± 1.1909 | -0.250 ± 0.4598 |
Blood samples were collected at Screening (within 14 days prior to dosing) and at Week 8, Taper visit (Week 9) and Follow-up visit (Week 10). Baseline was considered as the value obtained at Screening. Change from Baseline was calculated by subtracting the Baseline value from the specific post-Baseline values. Only those participants with data available at the specified time points were analyzed (represented by n=X in the category titles).
| Femtoliter | Bupropion XL | Escitalopram |
|---|---|---|
| MCV, Week 8, n=176, 183 | 4.668 ± 62.5158 | -0.090 ± 2.4759 |
| MCV, Taper, n=13, 16 | 0.508 ± 2.2291 | 0.181 ± 2.1201 |
| MCV, Follow-up, n=10, 8 | 0.320 ± 3.3565 | 0.287 ± 1.1205 |
Blood samples were collected at Screening (within 14 days prior to dosing) and at Week 8, Taper visit (Week 9) and Follow-up visit (Week 10). Baseline was considered as the value obtained at Screening. Change from Baseline was calculated by subtracting the Baseline value from the specific post-Baseline values. Only those participants with data available at the specified time points were analyzed (represented by n=X in the category titles).
| 10^12 cells per liter | Bupropion XL | Escitalopram |
|---|---|---|
| RBC Count, Week 8, n=176, 183 | -0.009 ± 0.2711 | -0.049 ± 0.2563 |
| RBC Count, Taper, n=13, 16 | -0.088 ± 0.1599 | -0.007 ± 0.2560 |
| RBC Count, Follow-up, n=10, 8 | -0.132 ± 0.4018 | 0.036 ± 0.1859 |
Urine samples were collected at Screening (within 14 days prior to dosing) and at Week 8, Taper visit (Week 9) and Follow-up visit (Week 10). Number of participants with urine specific gravity and potential of hydrogen (pH) outside (higher or lower) the normal range are presented. Only those participants with data available at the specified time points were analyzed (represented by n=X in the category titles).
| Participants | Bupropion XL | Escitalopram |
|---|---|---|
| Urine specific gravity, high,Screening, n=265, 255 | 20 | 12 |
| Urine specific gravity, low,Screening, n=265, 255 | 1 | 1 |
| Urine specific gravity,high, Week 8, n=171, 173 | 9 | 7 |
| Urine specific gravity,low, Week 8, n=171, 173 | 0 | 1 |
| Urine specific gravity, high, Taper, n=18, 28 | 0 | 0 |
| Urine specific gravity, low, Taper, n=18, 28 | 0 | 1 |
| Urine specific gravity, high, Follow-up, n=7, 14 | 0 | 3 |
| Urine specific gravity, low, Follow-up, n=7, 14 | 0 | 0 |
| Urine pH, high, Screening, n=265, 266 | 7 | 18 |
| Urine pH, low, Screening, n=265, 266 | 37 | 28 |
| Urine pH, high, Week 8, n=172, 178 | 5 | 9 |
| Urine pH, low, Week 8, n=172, 178 | 23 | 20 |
| Urine pH, high, Taper, n=18, 28 | 0 | 1 |
| Urine pH, low, Taper, n=18, 28 | 2 | 2 |
| Urine pH, high, Follow-up, n=7, 14 | 0 | 0 |
| Urine pH, low, Follow-up, n=7, 14 | 2 | 2 |
Vital signs including systolic blood pressure (SBP), diastolic blood pressure (DBP) and heart rate (HR) were taken at Screening (within 14 days prior to dosing), randomization visit (Week 0) and at Weeks 1, 2, 4, 6, 8, Taper visit (Week 9) and Follow-up visit (Week 10). SBP \<30 or \>170 millimeter of mercury (mmHg); DBP \<20 or \>110 mmHg and heart rate \<40 or \>120 beats per minute (bpm) were considered as values outside of clinical concern range and were presented as 'High' or 'Low' values. Number of participants with vital signs outside of clinical concern range at any post-Baseline visit are presented. Only those participants with data available at the specified time points were analyzed.
| Participants | Bupropion XL | Escitalopram |
|---|---|---|
| SBP, high, Any visit post-Baseline | 1 | 0 |
| SBP, low,Any visit post-Baseline | 0 | 0 |
| DBP, high, Any visit post-Baseline | 0 | 0 |
| DBP, low, Any visit post-Baseline | 0 | 0 |
| HR, high, Any visit post-Baseline | 0 | 1 |
| HR, low, Any visit post-Baseline | 0 | 0 |
ECG was recorded at Screening (within 14 days prior to dosing) and at Week 8, Taper visit (Week 9) and Follow-up visit (Week 10). PR interval \<110 or \>220 millisecond (msec); QRS interval \<60 or \>120 msec and corrected QT (QTc) interval \>450 msec were considered as values outside of clinical concern range and were presented as 'High' or 'Low' values. Number of participants with ECG data outside of clinical concern range at any post-Baseline visit are presented. Only those participants with data available at the specified time points were analyzed.
| Participants | Bupropion XL | Escitalopram |
|---|---|---|
| PR interval, high, Any visit post-randomization | 0 | 0 |
| PR interval, low,Any visit post-randomization | 5 | 2 |
| QRS interval, high, Any visit post-randomization | 2 | 3 |
| QRS interval, low, Any visit post-randomization | 0 | 1 |
| QTc interval, high, Any visit post-randomization | 1 | 3 |
| QTc interval, low, Any visit post-randomization | 0 | 0 |
CSFQ is a questionnaire about sexual activity and sexual function (sexual intercourse, masturbation, sexual fantasies and other activity). CSFQ is a gender-specific questionnaire. Both male and female versions consist of 14 items, each with 5 possible answers. CSFQ has a score in a range of 14 to 70. Higher score indicates higher sexual activity and sexual function. Value at Day 0 (Week 0) was considered as Baseline value. Change from Baseline at Week 8 was calculated by subtracting the Baseline score from the specific post-Baseline score. Only those participants with data available at the specified time points were analyzed.
| Scores on a scale | Bupropion XL | Escitalopram |
|---|---|---|
| Change From Baseline in Changes in Sexual Function Questionnaire (CSFQ) | 3.0 ± 6.47 | 0.9 ± 7.21 |
C-SSRS is an assessment tool that evaluates suicidal ideation and behavior. It consists of 10 items, each with two possible answers (yes/no). Suicidal ideation was interpreted if "yes" answer at any time during treatment to any one of the five suicidal ideation questions (item 1-5) on the C-SSRS. Suicidal behavior was interpreted if a "yes" answer at any time during treatment to any one of the five suicidal behavior questions (item 6-10) on the C-SSRS. Suicidal ideation or behavior is interpreted if a "yes" answer at any time during treatment to any one of the ten suicidal ideation and behavior questions (item 1-10) on the C-SSRS. Number of participants with at least one on-treatment C-SSRS assessment were analyzed. Only those participants with data available at the specified time points were analyzed.
| Participants | Bupropion XL | Escitalopram |
|---|---|---|
| Suicidal Ideation or Behavior | 50 | 43 |
| Suicidal Ideation | 50 | 43 |
| Suicidal Behavior | 2 | 1 |
| Self-Injurious Behavior, no suicidal attempt | 1 | 1 |
Collected over Adverse events (AEs) were collected from the start of study treatment and until the end safety follow-up visit (up to Week 10). SAEs were recorded from the time the consent form is signed until the follow-up visit (up to Week 10).. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Bupropion XL | 1/266 (0.4%) | 10/266 (3.8%) | 151/266 (56.8%) |
| Escitalopram | 0/268 (0%) | 11/268 (4.1%) | 150/268 (56%) |
| Event | Bupropion XL | Escitalopram |
|---|---|---|
| DepressionPsychiatric disorders | 2/266 | 4/268 |
| Depression suicidalPsychiatric disorders | 1/266 | 0/268 |
| Lacrimal structure injuryInjury, poisoning and procedural complications | 1/266 | 0/268 |
| OverdoseInjury, poisoning and procedural complications | 1/266 | 0/268 |
| Somatic symptom disorderPsychiatric disorders | 1/266 | 0/268 |
| TinnitusEar and labyrinth disorders | 1/266 | 0/268 |
| ConjunctivitisInfections and infestations | 1/266 | 0/268 |
| Suicide attemptPsychiatric disorders | 1/266 | 0/268 |
| UrticariaSkin and subcutaneous tissue disorders | 1/266 | 0/268 |
| Blood pressure increasedInvestigations | 0/266 | 1/268 |
| Event | Bupropion XL | Escitalopram |
|---|---|---|
| NauseaGastrointestinal disorders | 28/266 | 50/268 |
| DizzinessNervous system disorders | 25/266 | 23/268 |
| HeadacheNervous system disorders | 20/266 | 15/268 |
| Dry mouthGastrointestinal disorders | 16/266 | 15/268 |
| Viral upper respiratory tract infectionInfections and infestations | 15/266 | 13/268 |
| Decreased appetiteMetabolism and nutrition disorders | 11/266 | 15/268 |
| ConstipationGastrointestinal disorders | 14/266 | 9/268 |
| SomnolenceNervous system disorders | 1/266 | 13/268 |
| PalpitationsCardiac disorders | 11/266 | 5/268 |
| Abdominal discomfortGastrointestinal disorders | 9/266 | 9/268 |
| Age, Continuous(Years) | Bupropion XL | Escitalopram | Total |
|---|---|---|---|
| Mean | 36.9 ± 11.92 | 37.6 ± 12.09 | 37.3 ± 12.00 |
| Sex: Female, Male(Participants) | Bupropion XL | Escitalopram | Total |
|---|---|---|---|
| Female | 168 | 172 | 340 |
| Male | 98 | 96 | 194 |
| Race/Ethnicity, Customized(Participants) | Bupropion XL | Escitalopram | Total |
|---|---|---|---|
| Asian - East Asian Heritage | 266 | 268 | 534 |
Plan to share: Yes — IPD for this study will be made available via the Clinical Study Data Request site.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: IPD is available via the Clinical Study Data Request site (click on the link provided below)
Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.
Data sharing details ↗ · clinicalstudydatarequest.com
Ran from Feb 2015 to primary completion in Oct 2016, 20 months.
Results were first posted in Feb 2019, 2 years 4 months after primary completion.
Of 95 industry-sponsored phase 3 interventional studies under Depressive Disorder, Major, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 33. This study's 20 months is below that.
Counting every sponsor, half of 124 studies reached it within 27 months; a quarter within 21 and three quarters within 36.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Bupropion